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Salvia miltiorrhiza (danshen) is widely used for the clinical treatment of cerebral ischemia and cardiovas-
cular diseases. Its diverse molecular makeup of simple and poly hydroxycinnamic acids and diterpenoid
quinones are also associated with its beneficial health effects such as improved cognitive deficits in mice,
protection of neuronal cells, prevention of amyloid fibril formation and preformed amyloid fibril
disaggregation related to Alzheimer’s disease. Whilst the in vitro studies have therapeutic promise, the
anti-dementia effect/impact of danshen however depends on its absorbed constituents and pharmacoki-
netic properties. Both the water and lipid danshen fractions have been shown to have low oral bioavail-
ability and at physiological pH, the polyphenolic carboxylate anions are not brain permeable. To tap into
the many neuroprotective and other biological benefits of danshen, the key challenge resides in develop-
ing danshen nanopharmaceuticals, semi-synthetic pro-drug forms of its constituents to improve its
biocompatability, that is, absorption, circulation in bloodstream and optimization of BBB permeability.
 2013 The Authors. Published by Elsevier Ltd. All rights reserved.Over the last few decades, aging diseases such as dementia and
Alzheimer’s disease (AD) have evolved into a global epidemic in an
aging population. Physical and mental exercise and dietary regimes
can counteract the development of aging1 and dementia. AD is
characterized by depositions of amyloid proteins (Ab) and choliner-
gic neurotransmission deficits in the brain. Current therapeutic
intervention for AD is primarily based on the inhibition of brain
acetylcholinesterase (AChE) to improve the brain acetylcholine
levels. A noninvasive early detection protocol for the presence of
Ab would aid in the diagnosis of dementia onset prior to extensive
neuronal damage and provide a therapeutic window to combat the
disease.2 The complementation of such strategies with safe preven-
tivedrugsor tailored food supplementswill beneeded to combat the
epidemic of cognitive decline, a hallmark of aging.
Danshen analysis: A considerable body of information has
accumulated on the therapeutic potential of Chinese herbs
that are associated with improved cognition, enhancing the fight
against dementia diseases.3 Salvia miltiorrhiza known as danshen,
one of the most popular Chinese traditional herbs is used to
improve blood circulation4 in the treatment of cardiovascular
disorders, cerebrovascular diseases. The specific clinical uses of
danshen in China relate to angina pectoris, hyperlipidemia andischemic stroke. In this review, the emerging research surrounding
the anti-dementia/AD effects and mechanisms of danshen that
have been investigated/proposed in the last 10 years as illustrated
in Scheme 1 is presented.
Analysis of the chemical constituents of danshen revealed two
dominant classes of secondary metabolites. A family of lipid
soluble, hydrophobic diterpenoids known as tanshinones andwater
soluble, hydrophilic, polyphenolic combination of compounds
consistingmainly of caffeic acidmonomers, dimers, trimers or tetra-
mers in the form of Salvianolic acids. The tanshinones and polyphe-
nolic acids are unique to the Salvia genus5 and the eight major
constituents found in danshen were isolated using microwave
assisted extraction procedures.6 A synopsis of the amounts isolated,
chemical structures, oral bioavailability and neuroprotection
studies are presented in Table 1.
Danshen bioavailability: For clinical applications for the treat-
ment of cerebrovascular, cardiovascular, cognitive diseases, it is
necessary to determine how much danshen is required daily to
provide protection, and this depends on the bioavailability of its
constituents. Upon oral administration of danshen decoctions, bio-
availability generally designates simply the quantity or fraction of
the ingested dose that is absorbed, its metabolism and excretion.
Animal studies have provided data on the uptake, absorption,
metabolism and excretion of danshen constituents. Chromato-
graphic, spectrometric and spectroscopic analytical methods have
been utilized for the identification of the in vivo metabolites and
pharmacokinetic properties in the urine of miniature pigs after oral
administration of danshen decoctions.44
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bioavailability related to the uptake/absorption/metabolism/circu-
lation/excretion of ten phenolic substances present in the decoc-
tion shown is Scheme 2. These active phenolic compounds were
found to undergo metabolic transformations in the colon and liver
including hydrolytic reactions, glucuronidation, sulfation, methyl-
ation, hydrogenation, decarboxylation and glycine conjugation be-
fore being excreted in the urine. The analysis also revealed that 87
% of the urine metabolite fraction is attributed to protocatechuic
aldehyde, caffeic acid and danshensu, suggesting that these are
the most significant bioactives and that intestinal metabolism sig-
nificantly increased their concentration/circulation and therefore
their potential bioactivity. This is further supported by analysis
data that indicated that colonic polyphenol metabolism led to a
fourfold increase in the mono-phenolic fraction as shown in
Scheme 3 below.
Danshen metabolites: The metabolism of dietary plant mono-
phenolic hydroxycinnamic acids45 in both rats and human subjects
undergo metabolic transformations in the gastrointestinal tract,
intestinal mucosa, intestinal microflora, liver, and kidneys. It is
known that these modifications include dehydroxylation, demeth-
ylation, hydrogenation, O-methylation, sulfation, glucuronisation,
GSH conjugation, and/or glycination. The relative rates of urinary
excretion of caffeic and ferulic acid and their metabolites
range46–48 from 5.9 to 27%. In rats fed 2.8 mmol of caffeic acid
(505 mg), 11% of the ingested dose was excreted49 in the urine.
Studies with mice indicate that caffeic acid in the brain has neuro-
protective actions.50 For instance 12.4 ± 1.8 mg/100 g of caffeic
acid was detected in the brain of mice with a diet containing 2%
caffeic acid for 4 weeks.51 Furthermore, caffeic acid protected the
PC12 cells against Ab-induced cell death through the attenuation
of intracellular calcium influx and reduction of s phosphorylation
by the decrease to GSK-3b activation.52 However studies on male
Sprague–Dawley rats that ingested 140  106 dpm of [3-14C]
trans-caffeic acid, found that over the ensuing 72 h period, there
was little or no accumulation of radioactivity in body tissues,
including the brain.53 A large number of human and rat urine
metabolites have been reported for caffeic and ferulic acids includ-
ing aromatic hydroxy acids45 following their ingestion. In this
context it is noteworthy that in vitro studies54 have shown that
simple dihydroxybenzoic acid isomers exhibit different abilities
to dissociate preformed biotinyl-Ab (1–42) oligomers. Whilst it isknown that the rapid and extensive metabolism of free hydroxy-
cinnamic acids results in low plasma concentrations and their
rapid elimination from circulation, a complete analysis of the
concentration of caffeic acid administered, prodrug forms, its
conjugates and metabolite end products in plasma and brain is
therefore needed to determine the nature, bioavailability/
accessibility of caffeic acid related compounds/metabolites and
their brain permeability to evaluate and measure the extent and
significance of their contribution to the improvement of spatial
learning, memory and resistance to cognitive diseases.
Rosmarinic acid: The evaluation of a standardized extract from
the leaves of sage Salvia officinalis specifically indicated that its
main ingredient, rosmarinic acid11 as being able to reduce/protect
cultured rat pheochromocytoma [PC12] cells from multiple
b-amyloid peptide induced neurotoxicity insults including reactive
oxygen species generation, lipid peroxidation, DNA decomposition,
caspase-3-activation, tau protein hyperphosphorylation and inhi-
bition of phosphorylated p38 mitogen protein kinase activation.
In a mouse model, rosmarinic acid at a dose of 0.25 mg/kg pro-
tected against the impairment of memory by b-amyloid peptide
through scavenging of the peroxynitrite (ONOO) anion, leading
to the implication that daily consumption of culinary herbs
containing rosmarinic acid may chemo-protect against dementia.14
The utilization of nuclear magnetic resonance [NMR] spectrometer
techniques revealed the binding of rosmarinic acid, a major
component of the butanol extract of Salvia sclareoides, to Ab
oligomers,15 inhibited both Ab oligomerization and deposition.55
Also the effect of rosmarinic acid, methyl caffeate, and methyl
cinnamate on Ab peptide aggregation was evaluated with the thi-
oflavin T assay which supported the NMR results and confirming
that these natural compounds, methyl caffeate, methyl cinnamate,
and rosmarinic acid present in many herbs could have
multiple neuroprotective/therapeutic effects against AD. The oral
bioavailability of RA in Isodi Rubescentis extract by LC–MS-MS in
rat plasma56 was 13.96 (+/–) 3%. The multicomponent nature of
herbal teas effectively enhanced rosmarinic acid absorption10 by
intestinal Caco-2 cells to 43 %.
Polyphenolic acid bioavailability: The pig urinary metabolite44
data showed that salvianolic acids are rapidly metabolized, con-
sistent with the reported12 bioavalability studies that indicate
salvianolic acids have very limited uptake and absorption.
The bioavailability12 values of RA, Sal B and Sal A (derived from
Table 1
Bioactivity profiles of the major danshen constituents
Danshen constituent analysis in mg/g,
chemical structure
Oral bioavailability, in animal studies Neuroprotective effects
Danshensu [DSS] 0.24–0.35
Detected7 brain/blood ratio is 0.25, Pgp inhibition
enhanced brain uptake.8
Danshensu-cysteine compound cytoprotective against
H2O2-induced cell death.9
Rosmarinic acid, [RA] 2.4–3.5
RA absorption from herbal teas10 (in presence of
flavonoids), by intestinal Caco-2 cells increased to 43%.
Calcd abs bioavailability RA, Sal B and Sal A, 5.29%, 3.05%
and 2.50%, respectively.12 Carboxylate anionic
compounds do not penetrate BBB.13
Neuroprotection of PC12 cells from Ab-induced toxicity11
chemo-protection due to peroxynitrite scavenging,14 RA-
Ab binding inhibited Ab oligomerization/deposition.15
Salvianolic acid B [Sal B] 56–75
Oral bioavailability16,17 in freely moving rats was 2.3%,
addition of borneol12 improved bioavailability, and
pharmacokinetics; compounds with carboxylic acid
group do not readily cross BBB.13
Protection against Ab cytotoxicity,18 inhibition/disag-
gregation Ab fibrils, antioxidant protection19 against
Ab25–35, attenuates cholinergic and Ab dysfunctions and
counters brain injury20,21 potential treatment for vascular
dementia,22,23 treatment for neurodegenerative
disease.24
Salvianolic acid A [Sal A] 0.29–0.37
Biovailability in beagle dog25 1.47–1.84%; chemical
instability26 at pH >7 subtracts from bioavailability.
Polyphenolic acids with a free carboxylic group have a
very low effective brain penetration.27,13
Inhibition of granulocyte adherence.28 Prevents oxidative
stress, platelet aggregation, ischemia, and
hepatocirrhosis.28 Matrix Metalloproteinase inhibitor.29
Inhibition MKP-3 expression.30 Sal A inhibited Ab42 self-
mediated aggregation & disaggregated Ab42 aging
fibrils.31
Dihydro-tanshinone [DHT] 0.10–0.24
Tanshinone I [TI], 0.37–1.1
Low oral bioavailability.32 The co-presence of other
tanshinones and danxiongfang enhances CT
bioavailability by decreasing the efflux transport of CT by
P-glycoprotein.33
T1 better than TIIA for: inhibition amyloid aggregation of
amyloid-b peptide, disaggregation amyloid fibrils, and
protection cultured cells.34 T1 improves memory
impairments,35 via cellular kinase signaling.
Cryptotanshinone, [CT] 0.24–0.88
Tanshinone IIA, [TIIA] 0.91–2.6
When CT was dosed at 100 mg/kg the oral and intra
peritoneal bioavailability32 in rats was estimated as 2.1%
and 10.6%, respectively. A low molecular weight TIIA-
chitosan [1:9] solid dispersion36 resulted in complete
dissolution, accelerated absorption rate and 30%
improved oral bioavailability.
Animal studies with CT attenuated Ab deposition.37 CT
acting as AChEI results in memory improvement,38 causes
APP processing to non-Ab,39 by translocation of ADAM10
and PKC-a. TIIA neuroprotection against cerebral
ischemia via inhibition of macrophage migration
inhibitory factor,40 protection from hypoxia-induced
mitochondrial apoptosis,41 disaggregates Ab fibrils, anti-
hypoxia activity via Akt/Skp2/p27 pathway,42 protection
from Ab via calpain, p35/Cdk5 pathway.43
710 H. M. Hügel, N. Jackson / Bioorg. Med. Chem. Lett. 24 (2014) 708–716the AUC) of rats that received Sal acid extract orally in compari-
son to receiving the extract intravenously, were calculated to be
5.29%, 3.05% and 2.50%, respectively. Previously, the absolute bio-
availability of Sal B had been calculated to be 3.90% or 5.0% in therat with oral administration of Sal B in pure form,57,58 1.07% in the
beagle dog with oral administration of Sal acid extract,59 and 5.6%
in rabbit.60 The low bioavailability of Sal acids is the result of
inadequate absorption from the intestine and the first pass
Danshen decoction
3 monophenolics [20%] 12 polyphenolics [80%]
41 monophenolics [82%] 9 polyphenolics [18%]
Danshen urinary metabolites
Scheme 3. Comparison of the phenolic composition of danshen decoction and pig
urinary metabolites.
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to the oral administration of the Sal acid extract, the absolute bio-
availability values of RA, Sal B and Sal A were improved by
21.61%, 33.77% and 17.90%, respectively, after oral administration
of Sal acid extract plus the co-addition of borneol,12 suggesting
that borneol enhanced the intestinal absorption, and limited the
metabolism of SAs. This was consistent also with the finding of
the poor oral bioavailability of Sal A in beagle dogs25 calculated
to range from 1.47% to 1.84% reflecting its low oral absorption
and quick clearance.
Salvianolic acid A anti-amyloid activity: In vitro studies of Sal A62
found multiple modulation of Ab induced toxicity whereby:
 It inhibited Ab42 self-mediated aggregation and disaggregated
Ab42 aging fibrils.
 Significantly decreased Cu, Fe or Zn ion induced Ab aggregation,
thus suggesting that Sal A inhibits Ab aggregation through and
beyond its metal chelating activity.
 Sal A reduced the production of oxidative stress in SH-SY5Y cell
lines.
 Sal A is a neuroprotective agent against Ab42-induced toxicity in
a dose-dependent manner.
 Sal A at 50 and 200 lM attenuated Ab-induced paralysis in C.
elegans strain CL4176 through decreasing the levels of total Ab
(p = 0.005 and 0.008 lM, respectively).
 Molecular dynamic simulations demonstrated that Sal A inhibits
Ab self-aggregation through binding to the C-terminus and
therefore stabilizing the helical conformations.Polyphenolic acid metabolism: As outlined in Scheme 3 and as
illustrated in Scheme 4 danshen polyphenolics may be hydrolyzed
to monophenolics according to the pig urine metabolite profile.
After passing through the stomach, the unabsorbed salvianolic
acids are unstable above pH 7 complicating their metabolic profile
analysis.26 The analysis of Sal B in stress free rats revealed that the
oral bioavailability of Sal B in free ranging rats was calculated17 as
2.3%. This supports the findings that polyphenolic compounds un-
dergo extensive metabolism, are modified and transformed by co-
lonic micro-flora, and thereby catabolized into simple phenolic
acid derivatives that can readily be absorbed from the large intes-
tine.63 These small phenolic acid products may account for some of
the biological activity associated with polyphenolic phytochemi-
cals of danshen whereby the ester bond hydrolysis in rosmarinic
acid, salvianolic acids A and B would substantially increase the
concentration of danshensu. The brain to blood distribution ratio
of danshensu has been calculated7 as 0.25 ± 0.04 and it has been
suggested that the good BBB permeability of danshensu is most
likely due to its low molecular weight and its low 5% protein-bind-
ing rate. Recently it was demonstrated8 that the combination of
verapamil a P-gp inhibitor with danshensu increased the brain
concentration of danshensu. A danshensu-cystine9 conjugate
inhibited apoptosis via upregulation of heme oxygenase-1 expres-
sion in SH-SY5Y cells. Further studies are required to investigate
the neuroprotective properties of the hydrolysis products of the
constituents in danshen.
Salvianolic acid B bioactivities: Sal B was found18 to inhibit Ab fi-
bril aggregation with IC50 1.54–5.37 lM as well as destabilize pre-
formed Ab fibril IC50 5–5.19 lM in a dose- and time-dependent
manner and proved to be more effective than ferulic acid but less
active than curcumin in the inhibition of Ab1–40 aggregation. Sal
B (10 mg/kg, p.o.) inhibited64 GABAergic neurotransmitter system;
Sal B showed anti-inflammatory benefits,20 suppressed the expres-
sion of pro-inflammatory cytokines TNF-a and IL-1b, and enhanced
the expression of anti-inflammatory cytokines IL-10 and TGF-b1.
Danshensu and salvianolic acid B could protect21 PC-12 cells by
blocking Ab(25–35)-induced Ca2+-intake, lactate dehydrogenase
release, cell viability decrease and apoptosis, TI and DHTI inhibited
acetylcholinesterase in vitro.
Sal A inhibited granulocyte adherence28 by decreasing the
expression of intercellular cell adhesion molecule-1 in brain mi-
cro-vascular endothelial cells in the treatment of ischemic stroke.
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extract EGb 761 on Ab25–35 fibril formation and cytotoxicity to
PC12 cells revealed that both Sal B and EGb 761 inhibited the
formation of amyloid fibrils, protected PC12 cells from Ab25–35 in-
duced cytotoxicity, and also decreased ROS accumulation caused
by Ab25–35. Significantly, Sal B was much more efficient than EGb
761 in inhibiting Ab aggregation and in protecting PC12 cells from
Ab-induced cytotoxicity.65 The anti-inflammatory properties of Sal
B on interferon-gamma-induced JAK-STAT1activation, suggests a
molecular mechanism for potential therapeutic application for
vascular disorders.66
The redox transformations of the polyphenol EGCG to quinones
leading to covalent modifications of proteins67 and remodeling of
amyloid fibrils68 has been described. The three catechol rings in Sal
B can similarly be oxidized in the cellular environment to
electrophilic quinones providing potent anti-Ab neuroprotective
effectsvia Schiff basebinding toAbpeptide lysineaminegroups.This
wouldaccount for someof thepotent anti-oxidativeproperties of Sal
B and the other catechol containing polyphenolic constituents of
danshen. The water-soluble danshen decoction is therefore poten-
tially a potent pro-electrophilic mixture of compounds that may
become redox-responsive and oxidized to quinones by the cellular
oxidative-stress environment, resulting in amyloid protein remod-
eling and abating Ab-induced cytotoxicity.
Sal B was found to promote neuronal stem progenitor cells
(NSPCs) proliferation in vitro and in vivo.24 The Sal B delayed
post-ischemic treatment (7 days after ischemic stroke) with
25 mg/kg improved cognitive impairment after stroke in rats.
Whilst studies showed that Sal B promoted the adult hippocampus
neurogenesis and improved the cognitive functions in cerebral
ischemia rats, evidence that Sal B permeates the blood–brain bar-
rier to act on NSPCs is required. However the exact mechanism(s)
by which Sal B acts on adult neurogenesis remain unclear. Addi-
tional mechanistic research to confirm NSPCs proliferation by Sal
B on contributing to the cognitive improvement is required. The
data clearly demonstrated that Sal B was capable of promotingproliferation of NSPCs and improving the learning and memory
ability of cerebral ischemic rats. It was concluded that the Sal B
promoted NSPCs self-renewal and neurogenesis were at least in
part attributed to the PI3 K/Akt signaling pathway. These findings
suggest that Sal B or its more lipophilic metabolites, could act as
potential drugs for the treatment of brain injury or neurodegener-
ative disease.
BBB permeation: Useful reported guidelines69 for the physico-
chemical properties of a molecule that are consistent with the
potential for brain uptake include:
 CNS penetration decreased as MW increased.
 Compounds with MW <300 had brain/blood ratios of 2.2
compared to 0.1 for compounds with MW >700.
 CNS penetration was dependent on ionization state descending
in the order basic > neutral > zwitterionic > acidic molecules.
 CNS penetration increases with c logP, but this correlation is
weaker than that for MW.
From the analysis of the physicochemical properties and the
chemical structural profiles of CNS and non-CNS oral drugs,70
and the above molecular guidelines for brain penetration, this sug-
gests that the hydrophilic danshen polyphenolics with: high polar
surface area, negative logD values, high MW, with free carboxylic
acid group(s) (acidic pKa values ranging from 2 to 4) ionization
state affecting membrane permeability adversely in the case of
negatively charged species71 are unable to enter the brain by
trans-cellular passive diffusion72 through the lipid membranes that
compose the BBB.
BBB permeation of polyphenolics: Nature may have created useful
therapeutic agents against AD. Resveratrol in red wine, curcumin
in turmeric spice curry, epidemiological evidence has shown an
inverse correlation between wine and curry consumption and
decreased AD risk. In cell culture experiments polyphenol
compounds inhibit the formation and promote the dissociation
of Ab-fibrils by selective and reversible binding.73–75 The link
H. M. Hügel, N. Jackson / Bioorg. Med. Chem. Lett. 24 (2014) 708–716 713between polyphenols and their effects on AD is controversial. Some
contend that to date there have not emerged any definitive human
intervention studies that have substantiated in vitro claims con-
cerning the neuroprotective effect of polyphenols.76 The key ques-
tion is the degree of polyphenol brain penetration. Polyphenolics
cannot be readily CNS tailor-made/redesigned, and so a prodrug,
semi-synthetic property modification and/or a pharmaceutical for-
mulation strategy may improve herbal CNS uptake.
Prodrug, formulations, and brain uptake: For example the mask-
ing of the carboxylic acid group as the 1,3-diacetyl glyceride ester
prodrug of ketoprofen [2-(3-benzoylphenyl) propanoic acid]
Scheme 5 resulted in the 50-fold improved brain uptake.77,78 This
suggests that carboxylate-prodrug modifications of the danshen
hydrophilic constituents would increase their lipophilicity and
higher brain concentrations, however this benefit also increases
the polyphenol molecular weight. The increased utilization of
nanoparticle, lipid and biopolymer combination formulation has
resulted in improved pharmacokinetic properties and increased
oral bioavailability and plasma concentration of bioactive sub-
stances. After the oral administration of a salvianolic acid B-
phospholipid complex79 the peak plasma concentration (Cmax) of
salvianolic acid B-phospholipid complex nanoparticles was
3.4 lg/ml much higher than that of salvianolic acid B at 0.9 lg/ml.
Bioavailability of tanshinones: Over forty lipophilic constituents
collectively known as tanshinones and recognized as abietane
diterpenes with four ring structures including the 15,16-dihydro-
tanshinone I (DH-TI) tanshinone I (TI), cryptotanshinone (CT), tan-
shinone IIA (TIIA), shown in Table 1 have been characterized and
isolated. The most representative species that produce this type
of diterpenoids is S. miltiorrhiza.5 Furthermore the abietanes
(including rearranged abietanes) form the largest group of compo-
nents of Salvia plants and are ordered into nineteen subgroups.5
The recently collated pharmacokinetic data32 for DH-TI, TI, CT,
TIIA, indicated that:
 Despite their lipophilic nature, tanshinones exhibit poor bio-
availability80 with p.o. around 2.1% and ip 10.6% in rats,
attributed to their low water solubility, poor membrane perme-
ability, and the actions of the P-glycoprotein efflux pump.
 Intravenous administration was the most effective method of
tanshinone uptake, pharmacokinetic interactions81 can eventu-
ate between the hydrophobic tanshinones and Sal B of hydro-
philic extracts of danshen resulting in increased plasma levels
of both phases.
 The occurrence of metabolic transformations82 whereby in vivo
CT is dehydrogenated to TIIA, is prevalent in pigs and rats.CH3O
O
O OAc
OAc
Ketoprofen-prodrug 50 fold inreased brain uptake
Methyl caffeate
OH
OH
COOCH3
N-Acetyl caffeamide
OH
OH
CONHCOCH3
or
Danshen mono/polyphenolic esters
Scheme 5. Ketoprofen prodrug and pot The high diversity of compounds in danshen extracts can lead to
higher absorption83,37 and bioavailability81 of some of its con-
stituents, increasing the competition for the same intake trans-
porters, while promoting the inhibition of efflux transporters.
 Mixtures of diterpenoid tanshinones and danxingfang, improved
the absorption of CT, probably by effectively decreasing the
efflux transport of CT by P-glycoprotein.33
A promising approach to enhance the solubility/dissolution and
bioavailability of TIIA has been reported.36 A 5-fold increase in dis-
solution of TIIA base by a solid dispersion (SD) system with low-
molecular-weight chitosan (TIIA/LMC 1:9 ratio) was recorded.
The improved dissolution of the SD was mainly attributed to the
high dispersion of the drug as microcrystalline, nano-crystalline
or amorphous state in the carrier. Compared with TIIA powders,
the oral bioavailability of the physical mixture increased about
30% and this may be due to the absorption-promoting activity of
chitosan.
Bioactivities of tanshinones: The diterpenoids DHT and CT are
both mixed non-competitive inhibitors for hAChE and uncompeti-
tive inhibitors for hBChE. In hAChE, and from molecular docking
studies DHT and CT were found to adopt different orientations in-
side the active-site gorge.84,85 While both compounds interact with
the ACh enzyme mainly through hydrophobic interactions, DT was
predicted to form extra hydrogen bonds with Tyr337 and Gly120.
This binding mode would explain the difference in their inhibition
potencies towards hAChE. On the other hand, CT and DT are bound
at a similar position in hBChE that allows them to interact with the
product analogues, suggesting that they inhibit the enzyme
through blocking the dissociation of reaction products. Further
investigation on the interactions/molecular docking of these inhib-
itors to hAChE and hBChE may provide insight for designing of a
new class of AChE inhibitor. Tanshinones have been identified as
potent human carboxylesterase (CE) inhibitors86 and have been
found to modulate the metabolism/efficacy of the anticancer pro-
drug irinotecan (CPT-11) induced cytotoxicity by inhibiting human
CEs. Remedies containing tanshinones should be avoided when
individuals are taking esterified agents to avoid potential drug–
drug interactions.
As previously stated32 many studies have demonstrated the
anti-proliferation and pro-apoptosis activities of tanshinones
[T1, TIIA, CT, DHT1] on various cancer cells, involving multiple tar-
gets were all performed in cell culture models. It is difficult to esti-
mate how likely these targets and mechanisms can be translated
into in vivo applications because most of the reported studies did
not have in vivo data to support the pharmacodynamic targets.CH3O
O
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Scheme 6. Salvia officinalis brain penetrating phenolic diterpenoids, miltirone.
714 H. M. Hügel, N. Jackson / Bioorg. Med. Chem. Lett. 24 (2014) 708–716Ab-inhibition of tanshinones: The examination34 of the in vitro
inhibitory activity of TS1 and TSIIA, on the aggregation and toxicity
of Ab1–42 using atomic force microscopy, thioflavin-T (ThT) fluo-
rescence assays31 cell viability assays, and molecular dynamics
simulations suggested that:
 The (ThT) fluorescence assays showed that both TS1 and TSIIA
exhibit different albeit general inhibitory abilities to prevent
unseeded amyloid fibril formation.
 TS1 showed better inhibitory potency than TSIIA to disaggregate
preformed amyloid fibrils.
 Small amounts of tanshinones enabled the protection of
cultured SH-SY5Y cells against Ab-induced cell toxicity.
 Comparative molecular dynamic simulation results reveal a gen-
eral tanshinone binding mode to prevent Ab peptide association,
showing that both TS1 and TSIIA preferentially bind to a hydro-
phobic b-sheet groove formed by the C-terminal residues
of Isoleucine31-Methionine35 and Methionine35-Valine39 and
several aromatic residues.
 The differences in binding distribution, residues, sites, popula-
tion, and affinity between TS1-Ab and TSIIA-Ab systems also
interpret different inhibitory effects on Ab aggregation as
observed by in vitro experiments.
 Tanshinones, particularly TS1 compound, offer promising lead
compounds with dual protective role in anti-inflammation and
antiaggregation for further development of Ab inhibitors to
prevent and disaggregate amyloid formation.
Neuroprotection of tanshinones:DHTI, TI, TIIA, CT, have all been re-
ported to attenuate scopolamine induced learning and memory
impairments38 on the passive avoidance task.87 It has been pro-
posed88 that TIIA protects rat brain from pristine ischemic damage
in the cerebral cortex thatmight be correlatedwith induced nuclear
translocation of transducers of regulated cAMP response element
binding protein (CREB) activity (TORCs). TORC1upregulated expres-
sion of CREB and brain derived neurotrophic factor. Also the task
learning ability of scopolamine-treated rats evaluated by the
acquisition protocol of the Morris water maze was significantly re-
versed by CT (5 mg/kg) and the CT-fed rats were able to develop a
spatial searching strategy comparable to that of the control animals.
T1 in rats improved learning, memory, and ameliorates memory
impairment in mice via signal-regulated kinase signaling path-
way.35 The antioxidative activity of TIIA protected cultured cortical
neurons against Ab25–35-induced neurotoxicity89 and is an effective
neuroprotectiveagentviaPI3 K/AktactivationandGSK3bphosphor-
ylation.90 It provided protection against neuropathological changes
inducedbyAb (1–40) injection into the hippocampus.91 Danshen in-
creased the expressions of urokinase PA, cyclin D1, E and ERK, JNK,
and P38 MAP kinases via the FGF-2 signaling pathway in a dose-
dependent manner, indicating that danshen and tanshinone IIA
may enhance neuron regeneration,92 however optimum dose
requirements were not determined.
TIIA protected the brain from ischemic injury by suppressing the
oxidative stress and the radical-mediated inflammatory insult.93
The effects of CT, on amyloid precursor protein (APP) processing in
rat cortical neuronal cells overexpressing Swedish mutant human
APP695 was to decrease94 Ab generation in concentration-depen-
dent manner. Also the alpha-secretase (sAbPPa) activity was
increased toward the non-amyloidogenic product pathway. Further
studies39 suggested that CT-induced sAbPPa secretion is regulated
by a PKC-a and the ADAM10 cascade in neuroblastoma cells and
may be involved in the lowering of Ab production.
Compound screening for BBB permeation: To provide a guide for
the BBB penetration of natural and synthetic compounds, the
parallel artificial membrane permeation assay (PAMPA) for
the prediction of blood–brain barrier penetration (PAMPA-BBB)was developed.27,13 This innovative system models the rate of
trans-cellular passive diffusion of drugs across the BBB by measuring
the effective permeability (Pe, cm/s) using a porcine brain artificial
lipid membrane extract as the assay membrane, impregnated on a
solid filter support. When applied to the constituents of Salvia
officinalis the screening/analysis characterized epiisorosmanol,
and methyl carnosate, (Scheme 6) two phenolic diterpenes as
BBB permeable compounds supporting evidence for the beneficial
effects of sage extracts for treatment of memory disorders.95,96
These compounds also have structural similarity with miltirone a
diterpene ortho-quinone found in danshen, reported for its anti-
oxidative,97 anxiolytic effect,98,99 positive modulation on GABA (A)
receptor100 and anti-proliferative activities in multidrug-resistant
cancer cells.101 Importantly the PAMPA study exemplifies the possi-
ble brain penetration of carboxylate ester compounds as highly
relevant for the modification/increasing the brain penetration of
danshen hydrophilic and lipophilic compounds. The PAMPA-BBB
assay should find increased application for screening/predicting
passive blood–brain barrier penetration of herbal constituents.
Tanshinones, activities, interactions: Recent research has s ug-
gested and provided evidence43 that the neuroprotective proper-
ties of TIIA against the neurotoxicity of Ab (25–35) had increased
the viability of neurons and decreased expression of phosphory-
lated tau in neurons induced by Ab (25–35). TIIA maintained the
normal expression of p35 on peripheral membranes, and reduced
p25 expression in the cytoplasm. Tan IIA also inhibited the translo-
cation of Cdk5 from the nucleus into the cytoplasm of primary
neurons induced by Ab (25–35). These data suggested that tan
IIA possessed neuroprotective action and the protection may in-
volve calpain and the p35/Cdk5 pathway. The pharmacokinetics102
of CT and TIIA in rats after administration of the tanshinones
extract were significantly affected by the coexisting tanshinones.
Indicating that the herb–drug interactions occurring between
coexisting tanshinones and CT or TIIA affected their absorption,
transformation and metabolism.
Herbal-nanoformulation therapeutics: Chemical modifications
and novel formulations had beenmade to address the poor oral bio-
availability of tanshinones.32 Plasma levels of tanshinones in the nM
to sub-lMrangeswere commonly observedwith ip and oral admin-
istration. Danshenmechanistic and therapeutic relevance should be
interpretedwhenever possible with relevant pharmacokinetic data.
For clinical applications, Ab inhibitors should resist premature enzy-
matic degradation, target specific tissues, cross the blood brain bar-
rier (BBB), and facilitate nucleus uptake, while not inducing
inflammation, toxicity, and other adverse immune responses. The
facile brain penetration/concentrationof curcumin-solid lipid nano-
particles103 suggests that nano-pharmaceuticals, nano-composites,
nano-structured lipid materials is a rapidly emerging pharmaceuti-
cal science that may provide ways of improving oral bioavailability
and brain penetration of herbal-nano-formulations leading to more
efficient therapies. To facilitate the preparation of a fully blood–
brain permeable danshen, care and caution is required. The use of
unconventional formulations alters the pharmacokinetics and bio-
availability, leading to changes in experimental outcomes. Also
H. M. Hügel, N. Jackson / Bioorg. Med. Chem. Lett. 24 (2014) 708–716 715administration of artificially high and non-physiological levels of
compounds triggers the saturation of drug eliminationmechanisms.
There is growing evidence that compounds broken down in the
colon form a key part of the ‘in vivo bioavailability equation’ of nat-
ural products and related compounds that can occur in danshen,
botanical medicines, and also in fruit and vegetables products
and extracts. Furthermore, the colon-derived phenolic acids appear
to have in vitro anti-inflammatory activity, and to protect human
nerve cells against oxidative damage. There appears to be a natural
synergistic effect whereby the multiple components of danshen
work together to provide benefits including enhanced
bioavailability.
In vitro research suggests that both tanshinones and polyphen-
olics in danshen are the active constituents responsible for the
beneficial effects of this herb in AD treatment.
Tanshinones, the main lipophilic components extracted from
Chinese herb danshen, can inhibit Ab aggregation, disaggregate
Ab fibers, and reduce Ab-induced cell toxicity in vitro. However
therapeutic potency and efficacy issues are unresolved. The mono-
and polyphenolic danshen compounds have multiple specific and
non-specific Ab binding interactions; and could be very promising
therapeutic inhibitors with both antiaggregation and antioxidant
activities to protect neurons from Ab damage.
AD is a multifactorial disease involving a wide range of molec-
ular mechanisms/networks whereby proteins, enzymes, receptors,
cell signaling, becomes dysfunctional, making poly-diagnosis and
treatment challenging.104 It is unclear which factors are essential
for the pathogenesis of AD. In the longitudinal assessment of AD,
Ab deposition increases slowly from cognitive normality to moder-
ate105 severity of dementia. Extensive Ab deposition precedes cog-
nitive impairment, and is associated with the ApoE genotype and a
higher risk of cognitive decline over 1–2 years. However, cognitive
decline is only weakly related to change in Ab burden,106,107 under-
lining that the multi-pathological nature of dementia and AD in-
volves an umbrella of factors, some of which have a more direct
effect on symptom progression than Ab deposition/toxicity.
Metabolism, efficacy of danshen anti dementia constituents: Chi-
nese herbs show promise in the treatment108 of AD. The unique
mixture of caffeic acid monomers, dimers, trimers, tetramers,
with various quinone diterpenes in danshen represent the multi-
ple molecular/biological properties of danshen as outlined in
Scheme 1 that actively target to eradicate most of the root causes
of dementia-AD onset and may lead the future direction of new
drug development. The poor bioavailability of danshen and all
other natural products including fruit products, the cognitive
benefits of which are attributed to their polyphenol content
means that further research is necessary to develop the most
appropriate/effective form of their intake and treatment. A better
understanding of how the major danshen constituents impact
metabolic phenolic profiles and their bioavailability is critical to
development of herbal products designed to deliver specific anti
dementia health benefits. The potential/possible need to initiate
the herbal/natural products as neuroprotection therapy long be-
fore the onset of dementia symptoms suggests that lifestyle
changes need to be addressed through education platforms. All
these issues need to be incorporated into the design of future
human trials of herbal and natural products to defeat dementia.
We may never achieve complete eradication of cognitive decline,
but such a pursuit serves as a constant source of inspiration to
discover and develop new preventative therapies.
Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.bmcl.2013.12.042.These data include MOL files and InChiKeys of the most important
compounds described in this article.
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